Cart
Your cart is empty
Looks like you haven’t added anything yet, browse new arrivals below!
Continue ShoppingMedically Reviewed by Jennie Stanford
Recent advancements in treatments for Duchenne muscular dystrophy (DMD) are offering hope to patients and families. This progressive condition affects muscle function and requires comprehensive management strategies.
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder that primarily affects boys, leading to progressive muscle degeneration. Symptoms typically appear between ages 2 and 5, often resulting in a loss of mobility by early adolescence. Research underscores the necessity of early diagnosis and intervention to enhance quality of life. As reported by the CDC, DMD impacts approximately 1 in every 3,600 to 9,300 live male births, emphasizing its rarity yet profound effect on affected families.
It’s a common misconception that Duchenne muscular dystrophy is simply a mobility issue. In truth, DMD also significantly affects other organ systems, including respiratory and cardiac functions, which can lead to serious later complications. Some may think that treatment options are few, but in reality, ongoing research is continuously unveiling innovative therapies.
Duchenne muscular dystrophy affects approximately 1 in every 3,600 to 9,300 live male births, underscoring its rarity and significant impact on those it touches.
The median age of survival for males with DMD has improved to around 23.7 years, thanks to advancements in management and treatment strategies, according to data from the CDC.
Research indicates that treatment measures, like corticosteroids, can extend ambulation and enhance overall health, revealing a positive trend in managing DMD. As highlighted by BioSpace, the Duchenne muscular dystrophy drugs market is projected to hit USD 5.5 billion by 2032, driven by innovations in treatment surgeries and therapies.
Common treatment measures for Duchenne muscular dystrophy include corticosteroids to reduce inflammation and delay muscle degeneration. Additionally, innovative therapies, like gene therapy and exon-skipping treatments, are under investigation, targeting the genetic roots of DMD. According to NS Pharma, the efficacy of the exon-skipping therapy viltolarsen has recently shown promising outcomes in both ambulatory and non-ambulatory patients.
Updated on 20 Nov 2024
Medical Disclaimer: This website is not intended for the purpose of providing medical advice. This website’s information, content, and material are for informational purposes only and are not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Cadense Inc. may not be held liable for any damages whether incidental, ordinary or consequential. Cadense does not make any guarantee of any particular end result. Cadense makes no claims or guarantees of payment/reimbursement by any insurance companies. Cadense adaptive shoes are intended to provide greater mobility to those with walking difficulties.
Looks like you haven’t added anything yet, browse new arrivals below!
Continue Shopping